We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this piece, we will look at where Incyte Corporation (NASDAQ:INCY) ranks on the list.

With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of artificial intelligence, the Federal Reserve’s interest rate cut cycle, and an economy with lower inflation. As was the case during the coronavirus pandemic when historically low interest rates propelled markets to new highs only to come crashing when rates were hiked in 2022, the shifts that are currently taking place should also affect investors for the next couple of years at the very least.

Naturally, this merits a look at what professional analysts are projecting about the future. On this front, investment bank Goldman Sachs recently updated its long-term forecasts for the US stock market. In a research report titled ‘Global Strategy Paper No. 71,  the bank outlined that the upgrade is necessary due to market concentration. This ‘concentration’ refers to roaring investor interest in large and mega-cap stocks primarily due to enthusiasm surrounding artificial intelligence.

Since the biggest technology companies are also the heaviest investors in AI, market returns have also focused on them. As an illustration, consider the performance of the flagship S&P index which is up 30.64% over the past twelve months. Now, consider the performances of Wall Street’s top AI GPU stock, the software company behind Windows, the social networking giant that owns Facebook, Jeff Bezos’ eCommerce company, and the world’s leading search engine provider. Their shares have gained roughly 192.21%, 12.66%, 69.01%, 42.44%, and 27.63% over the same period. Consequently, most mega-cap stocks have driven the market in returns.

As per Goldman, this bifurcation implies that the equal-weight flagship S&P index is likely to outperform the market cap-weighted index “by an annualized 200 bp-800 bp” over the next decade, or between 2024 and 2034. To build its argument, the bank cites historical data which also covers the dotcom boom of the late 1990s and the early 2000s. This bubble is key in understanding today’s market, as it does share some characteristics with the surge in artificial intelligence stocks following OpenAI’s release of ChatGPT and Jensen Huang’s prediction of a trillion dollars of compute capacity waiting for an upgrade.

GS points out that the equal-weight S&P tends to underperform the market weight index sharply before the trend reverses. It cites the market’s performance of the two indexes before the bubble’s ‘pop’ to point out that “the trough in 10-year relative underperformance of the equal-weight vs. cap-weight index occurred during the lead-up to the Dot Com bubble (1990-2000).” This saw the equal weight index lag the market weight index by four percentage points (pp) at the trough or the bottom. After the bottom, the differential flipped and the equal weight index led its counterpart by close to seven points (pp). As per Goldman, the four-point shortfall “has been matched during the past decade (2014-2024E) as the aggregate index has been powered by a few mega-cap Tech stocks and AI euphoria.”

Linking historical performance trends with investor concentration in mega caps and AI stocks, the bank shares that this “extreme level of market concentration (99th percentile) suggests the magnitude of equal-weight outperformance over the next decade should also be stronger than average.” Just how strong can this be? Well GS outlines that the equal weight index can outperform the market weighed index by 8 percentage points. On the flip side, since this is the most bullish forecast, the bank notes that if equal weight index performance reverts to its historical mean over the past 50 years, then “this would imply a less dramatic 2 pp of annualized outperformance.”

While stock market math is all good, other factors also drive its performance. November has seen headlines talk about nothing else but the Presidential Election. Post-election stock performance saw some firms, like Elon Musk’s car company record stunning gains. Goldman’s Shawn Tuteja, who works with exchange-traded funds (ETFs) and baskets, shared some insights about what sectors performed well after the election and whether this outperformance will continue. In a podcast, he outlined that “the biggest themes that we saw play out the day after the election on Wednesday were regional banks and banks getting bought.” He shared that “any sectors that were linked to de-regulation, benefited.” These include “energy, traditional energy versus renewables” with the former up by 4% while the latter losing roughly 10%.

Tuteja added that “the resilience and strength of US tech over the past couple of days post the election” was a standout from the market’s post-election performance in 2016. As to what lies in the future, the Goldman analyst is optimistic. He believes that “what I would expect to come over the next couple of weeks is a continuation on the factor level of the themes that worked post the election.” This is because “it takes time for money to be deployed and for themes to play out.” According to him, in 2016, “regional banks and big banks rallied for months after the election and they outperformed all of the other sectors in the market.” Additionally, while the broader markets might have calmed at a surface level, Tuteja points out that “under the surface, those sector moves become a lot more violent as correlations in the market break, as people start picking winners and losers in the new government regime’s policies.”

For some bank stocks, you can check out 10 Best Local Bank Stocks To Invest In Now and 10 Best Diversified Bank Stocks to Buy Now.

Within this dynamic environment that will see the Fed continue to tailor its interest rate decisions to the economy and companies adjust to a looser monetary policy, firms might also increase their cash spending. In a note covering spending, Goldman shared that the benchmark S&P index firms can increase their spending to 11% next year from 2024’s 8%. This will be driven by rising profits, as the bank believes that earnings “growth alone can explain 40% of next quarter’s cash spending growth.”

Just like it expects equities performance to broaden in the future, the bank also posits that the “typical stock should close the earnings growth gap with the mega-cap tech stocks.” Finally, on the topic of mergers and acquisitions, which slowed down in the wake of historic interest rates, GS is optimistic. It expects “cash M&A will rebound by 20% in 2025,” but cautions that “the potential for tariffs, regulatory changes, and corporate tax reform could meaningfully shift these forecasts.”

Our Methodology

To make our list of Goldman Sachs’ top growth investment stocks, we used the bank’s recent list of stocks and picked out those with a growth investment ratio of 70% or higher. This ratio is defined as the ratio of capital expenditure and R&D spending excluding depreciation over a firm’s cash flow from operations.

For these stocks, we also mentioned the number of hedge fund investors. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).

Incyte Corporation (NASDAQ:INCY)

Growth Investment Ratio: 379%

Number of Hedge Fund Holders: 35

Incyte Corporation (NASDAQ:INCY) is a mid-sized Delaware-based biotechnology company. The firm’s profit has turned into a loss in 2024 as of H1 due to higher research and development spending. Incyte Corporation (NASDAQ:INCY) relies to a large extent on its products to generate revenue. For the first six months of the year, out of its $1.9 billion revenue, 84% or $1.6 billion came through products sold. Within the $1.6 billion, 81% was generated by Incyte Corporation (NASDAQ:INCY)’s JAKAFI medicine for myelofibrosis. Consequently, JAKAFI is central to the firm’s hypothesis, and in Q3, Incyte Corporation (NASDAQ:INCY) reported that the medicine drove its 24% annual revenue growth to $1.1 billion. The firm also impressed investors by raising its full-year JAKAFI revenue guidance to a midpoint of $2.755 billion from an earlier $2.73 billion.

Another key factor that drives the hypothesis of biotechnology firms is their drug development portfolio. Here’s what Incyte Corporation (NASDAQ:INCY)s management had to say on this front during the Q3 2024 earnings call:

“I want to highlight 3 products that are expected to begin contributing to revenue in the near-term.

We anticipate that Niktimvo for third-line chronic GVHD, tafasitamab for follicular lymphoma and retifanlimab for SCAC could collectively generate $800 million or more in incremental revenues by 2029. We anticipate all 3 products to be available in 2025 and this incremental sales will be leveraging the current commercial infrastructure used for Monjuvi, Pemazyre and Jakafi. As illustrated on Slide 10, these 3 launches anticipated in 2025 will be followed by larger opportunities in 2026 and 2027, including povorcitinib CDK2 and tafasitamab in first-line DLBCL. Between 2027 and 2030, we have multiple programs that hold transformative potential with data for each anticipated in 2025.”

Overall, INCY ranks 2nd on our list of Goldman Sachs’ top growth investors. While we acknowledge the potential of INCY as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INCY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.